Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.83 |
| ▸ | CDK8 | P49336 | 1/20 | 0.83 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.83 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.78 |
| ▸ | CLK1 | P49759 | 2/20 | 0.78 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.78 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.78 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.78 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.75 |
| ▸ | SGK1 | O00141 | 4/20 | 0.74 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.70 |
| ▸ | KIT | P10721 | 3/20 | 0.68 |
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941685 | 0.91 | AXL (1.00) | AXLCDK8TNIKNTRK1CLK1 | |
| SCHEMBL18576768 | 0.87 | NTRK1 (1.00) | AXLCDK8TNIKNTRK1CLK1 | |
| SCHEMBL29337149 | 0.87 | NTRK1 (0.90) | AXLCDK8TNIKNTRK1DYRK1A | |
| SCHEMBL4173910 | 0.87 | NTRK1 (0.70) | AXLCDK8TNIKNTRK1CLK1 | |
| SCHEMBL3769633 | 0.87 | NTRK1 (0.76) | AXLCDK8TNIKNTRK1CLK1 | |
| SCHEMBL722564 | 0.86 | MAP3K11 (1.00) | AXLCDK8TNIKNTRK1CLK1 | |
| SCHEMBL15833892 | 0.86 | DYRK1A (0.89) | AXLCDK8TNIKCLK1DYRK1A | |
| SCHEMBL8320989 | 0.86 | AXL (0.83) | AXLCDK8TNIKNTRK1CLK1 | |
| SCHEMBL3771174 | 0.86 | DYRK1A (0.89) | AXLCDK8TNIKCLK1DYRK1A | |
| SCHEMBL3759528 | 0.85 | AXL (0.81) | AXLCDK8TNIKNTRK1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | claimed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | claimed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | claimed |
| WO-2021006707-A1 | USE OF SGK1 INHIBITOR AS THERAPEUTIC AGENT FOR INFLAMMATORY NEUROLOGICAL DISEASES | 한양대학교 산학협력단 | 2021-01-14 | — | — | WO | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2010049173-A1 | USE OF INHIBITORS OF HOST KINASES FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2010-05-06 | — | — | WO | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | AXL 1252/4885CDK8 142/4885TNIK 68/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | AXL 1252/4885CDK8 142/4885TNIK 68/4885 |
| US-20140249138-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | AXL 1252/4885CDK8 142/4885TNIK 68/4885 |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | AXL 1542/4885CDK8 525/4885TNIK 212/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | AXL 1432/4885CDK8 639/4885TNIK 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.